The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
Open accessAbstract
Objective: To better define the rare adverse event (AE) of diabetes mellitus associated with immune checkpoint inhibitors (ICIs). Design and methods: We report the case of a lung cancer patient with diabetic ketoacidosis (DKA) and autoimmune thyroiditis during pembrolizumab treatment. We provide a systematic review of all published cases (PubMed/Web of Science/Cochrane, through November 2018) of autoimmune diabetes mellitus related to blockade of the cytotoxic T-lymphocyte antigen 4 (CTLA-4)-, programmed cell death 1 (PD-1) receptor or its ligand (PD-L1) or combination (ICI) therapy. Results: Our literature search identified 90 patient cases (our case excluded). Most patients were treated with anti-PD-1 or anti-PD-L1 as monotherapy (79%) or in combination with CTLA-4 blockade (15%). On average, diabetes mellitus was diagnosed after 4.5 cycles; earlier for combination ICI at 2.7 cycles. Early-onset diabetes mellitus (after one or two cycles) was observed during all treatment regimens. Diabetic ketoacidosis was present in 71%, while elevated lipase levels were detected in 52% (13/25). Islet autoantibodies were positive in 53% of patients with a predominance of glutamic acid decarboxylase antibodies. Susceptible HLA genotypes were present in 65% (mostly DR4). Thyroid dysfunction was the most frequent other endocrine AE at 24% incidence in this patient population. Conclusion: ICI-related diabetes mellitus is a rare but often life-threatening metabolic urgency of which health-care professionals and patients should be aware. Close monitoring of blood glucose and prompt endocrine investigation in case of hyperglycemia is advisable. Predisposing factors such as HLA genotype might explain why some individuals are at risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 2×
“Definite conclusions remain difficult as PD-L1 also binds to B7-1 (CD-80), itself a ligand for CD-28 and CTLA-4 (84).”
BackgroundBrahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175 · cited 1×
“polymorphisms in the CTLA4 and PD-1 gene confer increased susceptibility to a variety of autoimmune disorders, including T1D (87-92).”
BackgroundA Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
The many faces of diabetes: a disease with increasing heterogeneity
Tuomi, T., Santoro, N., Caprio, S., Cai, M., Weng, J., & Groop, L. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62219-9 · Cited by 652
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649
Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses
Liang, S. C., Latchman, Y. E., Buhlmann, J. E., Tomczak, M. F., Horwitz, B. H., Freeman, G. J., & Sharpe, A. H. (2003) · European Journal of Immunology · doi:10.1002/eji.200324228 · Cited by 639
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590 · cited 7×
“the time of diagnosis is related to an earlier onset of ICI-induced diabetes (4, 6, 43, 58).”
BackgroundResultInfluentialHyponatremia: evaluating the correction factor for hyperglycemia
Hillier, T. A., Abbott, R. D., & Barrett, E. J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00055-8 · Cited by 567
Brahmer, J. R., Lacchetti, C., & Thompson, J. A. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00005 · Cited by 377
Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B., & Herold, K. C. (2015) · Diabetes Care · doi:10.2337/dc14-2349 · Cited by 347
Long, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., et al. (2012) · Diabetes · doi:10.2337/db12-0049 · Cited by 314
Steck, A. K., & Rewers, M. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.148221 · Cited by 310
Pihoker, C., Gilliam, L. K., Hampe, C. S., & Lernmark, A. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s52 · Cited by 303
Sznol, M., Postow, M. A., Davies, M. J., Pavlick, A. C., Plimack, E. R., Shaheen, M., Veloski, C., & Robert, C. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.002 · Cited by 290
Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278
Adult-onset autoimmune diabetes: current knowledge and implications for management
Buzzetti, R., Zampetti, S., & Maddaloni, E. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.99 · Cited by 271 · cited 1×
“Table 4 compares the characteristics of the different diabetes subtypes (78, 107-113).”
BackgroundImagawa, A., Hanafusa, T., Awata, T., Ikegami, H., Uchigata, Y., Osawa, H., Kawasaki, E., Kawabata, Y., Kobayashi, T., Shimada, A., et al. (2012) · Journal of Diabetes Investigation · doi:10.1111/jdi.12024 · Cited by 249
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244
Nielsen, C., Hansen, D., Husby, S., Jacobsen, B. B., & Lillevang, S. T. (2003) · Tissue Antigens · doi:10.1046/j.1399-0039.2003.00136.x · Cited by 232 · cited 1×
“polymorphisms in the CTLA4 and PD-1 gene confer increased susceptibility to a variety of autoimmune disorders, including T1D (87-92).”
BackgroundProgrammed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus
Clotman, K., Janssens, K., Specenier, P., Weets, I., & De Block, C. E. M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00728 · Cited by 232
Hanafusa, T., & Imagawa, A. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0351 · Cited by 210
The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
Paterson, A. M., Brown, K. E., Keir, M. E., Vanguri, V. K., Riella, L. V., Chandraker, A., Sayegh, M. H., Blazar, B. R., Freeman, G. J., & Sharpe, A. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003496 · Cited by 202
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190
Colli, M. L., Hill, J. L. E., Marroquí, L., Chaffey, J., Dos Santos, R. S., Leete, P., Coomans de Brachène, A., Paula, F. M. M., Op de Beeck, A., Castela, A., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.040 · Cited by 189
Kavvoura, F. K., & Ioannidis, J. P. A. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi165 · Cited by 173
Yadav, D. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02072-4 · Cited by 171
Differential expression of CTLA-4 among T cell subsets
JAGO, C. B., YATES, J., OLSEN SARAIVA CÂMARA, N., LECHLER, R. I., & LOMBARDI, G. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02478.x · Cited by 167
Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
Gaudy, C., Clévy, C., Monestier, S., Dubois, N., Préau, Y., Mallet, S., Richard, M.-A., Grob, J.-J., Valéro, R., & Béliard, S. (2015) · Diabetes Care · doi:10.2337/dc15-1331 · Cited by 159
Fulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapy
Okamoto, M., Okamoto, M., Gotoh, K., Masaki, T., Ozeki, Y., Ando, H., Anai, M., Sato, A., Yoshida, Y., Ueda, S., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12531 · Cited by 155
Osum, K. C., Burrack, A. L., Martinov, T., Sahli, N. L., Mitchell, J. S., Tucker, C., Pauken, K. E., Papas, K. K., Balamurugan, A. N., Spanier, J. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26471-9 · Cited by 151
Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
Mellati, M., Eaton, K. D., Brooks‐Worrell, B., Hagopian, W., Martins, R. G., Palmer, J. P., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0889 · Cited by 145
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0810 · Cited by 142
Godwin, J. L., Jaggi, S., Sirisena, I., Sharda, P., Rao, A. D., Mehra, R., & Veloski, C. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0245-2 · Cited by 140
Kawasaki, E., Matsuura, N., & Eguchi, K. (2006) · Diabetologia · doi:10.1007/s00125-006-0213-8 · Cited by 138
Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
Martín-Liberal, J., Furness, A. J. S., Joshi, K., Peggs, K. S., Quezada, S. A., & Larkin, J. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1689-1 · Cited by 137
Gauci, M.-L., Laly, P., Vidal-Trécan, T., Baroudjian, B., Gottlieb, J., Madjlessi-Ezra, N., Meda, L. D., Madelaine, I., Bagot, M., Basset‐Séguin, N., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2033-8 · Cited by 137
Higham, C. E., Olsson-Brown, A., Carroll, P., Cooksley, T., Larkin, J., Lorigan, P., Morganstein, D., Trainer, P. J., & _, _. (2018) · Endocrine Connections · doi:10.1530/ec-18-0068 · Cited by 136
Abnormalities of the Exocrine Pancreas in Type 1 Diabetes
Campbell‐Thompson, M., Calvo, T. R., & Battaglia, M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0653-y · Cited by 130
Diabetes mellitus: diagnosis and screening.
Patel, P., & Macerollo, A. A. (2010) · PubMed · Cited by 127
Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
Wright, J. J., Salem, J., Johnson, D. B., Lebrun‐Vignes, B., Stamatouli, A. M., Thomas, J. W., Herold, K. C., Moslehi, J. J., & Powers, A. C. (2018) · Diabetes Care · doi:10.2337/dc18-1465 · Cited by 127
Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1913-7 · Cited by 121 · cited 1×
“Additionally, the authors reviewed the reference lists of the included articles (4, 13-68) and identified 5 additional cases (69-72).”
BackgroundVerge, C. F., Howard, N. J., Rowley, M. J., Mackay, I. R., Zimmet, P., Egan, M., Hulinska, H., Hulinsky, I., Silvestrini, R. A., Kamath, S., et al. (1994) · Diabetologia · doi:10.1007/bf00418375 · Cited by 121
Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells
Gray, C. P., Arosio, P., & Hersey, P. (2002) · Blood · doi:10.1182/blood.v99.9.3326 · Cited by 118
Blomhoff, A., Lie, B. A., Myhre, A. G., Kemp, E. H., Weetman, A. P., Akselsen, H. E., Huseby, E. S., & Undlien, D. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031854 · Cited by 115
Fujisawa, R., Haseda, F., Tsutsumi, C., Hiromine, Y., Noso, S., Kawabata, Y., Mitsui, S., Terasaki, J., Ikegami, H., Imagawa, A., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12603 · Cited by 115
Lowe, J. R., Perry, D. J., Salama, A. K. S., Mathews, C. E., Moss, L. G., & Hanks, B. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0196-z · Cited by 110
Gerold, K. D., Zheng, P., Rainbow, D. B., Zernecke, A., Wicker, L. S., & Kissler, S. (2011) · Diabetes · doi:10.2337/db11-0130 · Cited by 102
Marchand, L., Thivolet, A., Dalle, S., Chikh, K., Reffet, S., Vouillarmet, J., Fabien, N., Cugnet‐Anceau, C., & Thivolet, C. H. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1234-8 · Cited by 100
Aleksova, J., Lau, P. K. H., Soldatos, G., & McArthur, G. A. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-217454 · Cited by 98
Hansen, E., Sahasrabudhe, D. M., & Sievert, L. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1835-4 · Cited by 93
Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
Miyoshi, Y., Ogawa, O., & Oyama, Y. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.239.155 · Cited by 93
Tsutsumi, C., Imagawa, A., Ikegami, H., Makino, H., Kobayashi, T., & Hanafusa, T. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00139.x · Cited by 84
Munakata, W., Ohashi, K., Yamauchi, N., & Tobinai, K. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2101-4 · Cited by 81
Ni, R., Ihara, K., Miyako, K., Kuromaru, R., Inuo, M., Kohno, H., & Hara, T. (2007) · Human Genetics · doi:10.1007/s00439-006-0309-8 · Cited by 78
Remón, J., Mezquita, L., Corral, J., Vilariño, N., & Reguart, N. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.52 · Cited by 74
Kapke, J. T., Shaheen, Z. R., Kilari, D., Knudson, P. E., & Wong, S. J. (2017) · Case Reports in Oncology · doi:10.1159/000480634 · Cited by 73
Usui, Y., Udagawa, H., Matsumoto, S., Imai, K., Ohashi, K., Ishibashi, M., Kirita, K., Umemura, S., Yoh, K., Niho, S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.015 · Cited by 72
Type 1 Diabetes and Interferon Therapy
Nakamura, K., Kawasaki, E., Imagawa, A., Awata, T., Ikegami, H., Uchigata, Y., Kobayashi, T., Shimada, A., Nakanishi, K., Makino, H., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2274 · Cited by 68
Phenotypic and genetic analyses of T‐cell‐mediated immunoregulation in patients with Type 1 diabetes
Tsutsumi, Y., Jie, X., Ihara, K., Nomura, A., Kanemitsu, S., Takada, H., & Hara, T. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01951.x · Cited by 63
Perri, V., Russo, B., Crinò, A., Schiaffini, R., Giorda, E., Cappa, M., Rosado, M. M., & Fierabracci, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922584 · Cited by 53
Sakurai, K., Niitsuma, S., Sato, R., Takahashi, K., & Arihara, Z. (2018) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.244.33 · Cited by 52
Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature
Hickmott, L., Peña, H. D. L., Turner, H. E., Ahmed, F., Protheroe, A. S., Grossman, A. B., & Gupta, A. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0480-y · Cited by 51
Gunawan, F., George, E., & Roberts, A. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0146 · Cited by 49
Case of type 1 diabetes associated with less‐dose nivolumab therapy in a melanoma patient
Teramoto, Y., Nakamura, Y., Asami, Y., Imamura, T., Takahira, S., Nemoto, M., Sakai, G., Shimada, A., Noda, M., & Yamamoto, A. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13486 · Cited by 47
Michot, J., Ragou, P., Carbonnel, F., Champiat, S., Voisin, A.-L., Mateus, C., Lambotte, O., & Annereau, M. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000202 · Cited by 47
Shiba, M., Inaba, H., Ariyasu, H., Kawai, S., Inagaki, Y., Matsuno, S., Iwakura, H., Yamamoto, Y., Nishi, M., & Akamizu, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9518-17 · Cited by 47
Meyers, D. E., Hill, W. F., Suo, A., Jimenez-Zepeda, V. H., Cheng, T., & Nixon, N. A. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0098-5 · Cited by 45
Heimberg, H., Nagy, Z. P., Somers, G., Leeuw, I. D., & Schuit, F. C. (1992) · Human Immunology · doi:10.1016/0198-8859(92)90046-p · Cited by 44
Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
Li, L., Masood, A., Bari, S., Yavuz, S., & Grosbach, A. (2017) · Case Reports in Oncology · doi:10.1159/000456540 · Cited by 44
Diabetic ketoacidosis induced by a single dose of pembrolizumab
Maamari, J., Yeung, S. J., & Chaftari, P. S. (2018) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2018.10.040 · Cited by 43
der Auwera, B. J. R. V., Schuit, F. C., Weets, I., Ivens, A., Autreve, J. E. V., & Gorus, F. (2002) · Human Immunology · doi:10.1016/s0198-8859(01)00362-7 · Cited by 42
Self-citationRestoring Regulatory T Cells in Type 1 Diabetes
Spence, A. L., & Tang, Q. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0807-6 · Cited by 42
Ishikawa, K., Saito‐Shono, T., Yamate, T., Yoshitaka, K. A. I., Sakai, T., Shimizu, F., Yamada, Y., Mori, H., Noso, S., Ikegami, H., et al. (2017) · European Journal of Dermatology · doi:10.1684/ejd.2016.2923 · Cited by 41
Hemoglobin A1c is a reliable criterion for diagnosing type 1 diabetes in childhood and adolescence
Ehehalt, S., Gauger, N., Blumenstock, G., Feldhahn, L., Scheffner, T., Schweizer, R., Neu, A., & for the DIARY-Group Baden-Wuerttemberg (2010) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00633.x · Cited by 40
Araújo, M., Ligeiro, D., Costa, L., Marquês, F., Trindade, H., Correia, J. M., & Fonseca, C. (2017) · Immunotherapy · doi:10.2217/imt-2017-0020 · Cited by 40
Diabetes and blood glucose disorders under anti-PD1
Magis, Q., Gaudy-Marqueste, C., Basire, A., Loundou, A., Malissen, N., Troin, L., Monestier, S., Mallet, S., Hesse, S., Richard, M.-A., et al. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000218 · Cited by 39
Granados, H., Draghi, A., Tsurutani, N., Wright, K., Fernandez, M. L., Sylvester, F. A., & Vella, A. T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183887 · Cited by 39
Gauci, M.-L., Boudou, P., Baroudjian, B., Vidal-Trécan, T., Meda, L. D., Madelaine, I., Basset‐Séguin, N., Bagot, M., Pagès, C., Mourah, S., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2178-0 · Cited by 39
Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma
Tsiogka, A., Jansky, G. L., Bauer, J. W., & Koelblinger, P. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000384 · Cited by 37
Case Report: Pembrolizumab-Induced Type 1 Diabetes in a Patient with Metastatic Cholangiocarcinoma
Smith-Cohn, M., Gill, D. M., Voorhies, B. N., Agarwal, N., & Garrido‐Laguna, I. (2017) · Immunotherapy · doi:10.2217/imt-2017-0042 · Cited by 37
Chan, P. Y., Hall, P. E., Hay, G. R., Cohen, V. M. L., & Szlosarek, P. W. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12607 · Cited by 36
Marchand, L., Paulus, V., Fabien, N., Pérol, M., Thivolet, C. H., Vouillarmet, J., & Saintigny, P. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.021 · Cited by 36
Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis
Tzoulis, P., Corbett, R., Ponnampalam, S., Baker, E., Heaton, D., Doulgeraki, T., & Stebbing, J. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0111 · Cited by 34
Diabetes associated with immune checkpoint inhibition: presentation and management challenges
Galligan, A., Xu, W., Fourlanos, S., Nankervis, A. J., Chiang, C. Y., Mant, A. M., Parente, P., Rischin, D., Krishnamurthy, B., Sandhu, S. K., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13762 · Cited by 33
Matsumura, K., Nagasawa, K., Ôshima, Y., Kikuno, S., Hayashi, K., Nishimura, A., Okubo, M., Uruga, H., Kishi, K., Kobayashi, T., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12679 · Cited by 32
Kumagai, R., Muramatsu, A., Nakajima, R., Fujii, M., 戒能賢太, Katakura, Y., Okumura, N., Ohara, G., Kagohashi, K., Satoh, H., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12627 · Cited by 32
Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy
Lee, S., Morgan, A., Shah, S. S., & Ebeling, P. R. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0021 · Cited by 32
Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
Changizzadeh, P. N., Mukkamalla, S. K. R., & Armenio, V. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0303-9 · Cited by 31
Shieh, S., Chou, F., Yu, P., Lin, W., Chang, D., Roffler, S. R., & Sytwu, H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900679 · Cited by 30
Thoreau, B., Gouaillier-Vulcain, F., Machet, L., Mateus, C., Robert, C., Ferreira-Maldent, N., Maillot, F., & Lioger, B. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2504 · Cited by 29
New onset diabetes after nivolumab treatment
Capitão, R., Bello, C., Fonseca, R. C., & Saraiva, C. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-220999 · Cited by 29
A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment
Humayun, M. A., & Poole, R. (2016) · HORMONES · doi:10.14310/horm.2002.1656 · Cited by 28
Ho, W. J., Rooper, L. M., Sagorsky, S., & Kang, H. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0348-4 · Cited by 27
Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies
Way, J., Drakaki, A., Drexler, A., & Freeby, M. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-220415 · Cited by 26
Szepietowska, B., Głębocka, A., Puch, U., Górska, M., & Szelachowska, M. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.29527 · Cited by 25
Leonardi, G. C., Oxnard, G. R., Haas, A. V., Lang, J. P., Williams, J. S., & Awad, M. M. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000173 · Cited by 24
Alhusseini, M., & Samantray, J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.05.007 · Cited by 23
New-onset insulin-dependent diabetes due to nivolumab
Zaied, A. A., Aktürk, H. K., Joseph, R. W., & Lee, A. S. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0174 · Cited by 23
Teló, G. H., Carvalhal, G. F., Cauduro, C. G. D. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw447 · Cited by 22
Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma
Takahashi, A., Tsutsumida, A., Namikawa, K., & Yamazaki, N. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000418 · Cited by 22
Rs2227982 and rs2227981 in PDCD1 gene are functional SNPs associated with T1D risk in East Asian
Gu, Y., Xiao, L., Gu, W., Chen, S., Feng, Y., Wang, J., Wang, Z., Cai, Y., Chen, H., Xu, X., et al. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1152-9 · Cited by 22
Matsuura, N., Koh, G., Konishi, C., Minamino, S., Takahara, Y., Harada, H., Kodama, K., & Emoto, M. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2203-3 · Cited by 22
Nivolumab-induced thyroid dysfunction in patients with lung cancer
Ramos-Levi, A. M., Rogado, J., Sánchez-Torres, J. M., Colomer, R., & Marazuela, M. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.05.005 · Cited by 20
Combination avelumab and utomilumab immunotherapy can induce diabetic ketoacidosis
Atkins, P., & Thompson, D. M. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.005 · Cited by 17
A Case of Drug-Induced Severe Endocrinopathies
Villarreal, J., Townes, D. A., Vrablik, M. E., & Ro, K. A. (2018) · Advanced Emergency Nursing Journal · doi:10.1097/tme.0000000000000173 · Cited by 12
Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab
Omodaka, T., Kiniwa, Y., Sato, Y., Suwa, M., Sato, M., Yamaguchi, T., Sato, A., Miyake, T., & Okuyama, R. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14331 · Cited by 8
Cited by
Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A. R., Wick, W., Kostine, M., Peters, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.001 · Cited by 1,311
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)
Roep, B. O., Thomaidou, S., van Tienhoven, R., & Zaldumbide, A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00443-4 · Cited by 623
Self-citationEndocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Darnell, E. P., Mooradian, M. J., Baruch, E. N., Yilmaz, M., & Reynolds, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0897-9 · Cited by 380
Metadata
- Authors
- de Filette, J. M. K., Pen, J. J., Decoster, L., Vissers, T., Bravenboer, B., Van der Auwera, B. J., Gorus, F. K., Roep, B. O., Aspeslagh, S., Neyns, B., Velkeniers, B., & Kharagjitsingh, A. V.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-09
- Volume
- 181
- Issue
- 3
- Pages
- 363-374
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2962807330
- Cited by
- 275
- References
- 112
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.